|
ABOUT PARTNERS |
CAR T-REX consortium comprises three academic and two industrial partners
across Europe and Israel
|
The consortium brings together a recognised multidisciplinary team with unique expertise and capabilities in genome editing, non-viral gene delivery, immunology and T cell therapy, as well as Quality-by-Design methodologies and cGMP manufacturing.
|
Stemmatters
Project coordinator
Project coordinator
Stemmatters is a contract development and manufacturing organisation (CDMO) operating in the manufacturing of regenerative medicine (RM) products such as cell therapies and cell-derived biologicals. The company addresses needs in product development and cGMP production, supporting the clinical translational and future commercialisation of high-impact medicinal products.
Stemmatters will adopt Quality-by-design (QbD) and risk assessment methodologies during product/process development, while levering its scientific and regulatory know-how to ensure a faster clinical translation of the CAR T cell therapy into the clinical setting.
|
TargetGene Biotechnologies
TargetGene was founded in 2012 in Israel by Drs. Dan Weinthal and Yoel Shiboleth following their 2011 invention of RNA-guided nucleases for genome editing. TargetGene is a pioneer in the gene-editing field with its proprietary best-in-class T-GEE (Genome Editing Engine) platform. The company is leveraging T-GEE's advantages to develop safe and effective cell-therapies for cancer and immune-related diseases via its proprietary "genetic-circuit rewiring" concept.
TargetGene brings expertise in new technologies for gene editing human cells. T-GEE technology displays higher specificity and lower off-target events compared to the gold-standard CRISPR/Cas9, improving the safety of gene delivery systems.
|
CiQUS, Universidade de Santiago de Compostela (USC)
Since 2011, the Centro Singular de Investigación en Química Biolóxica y Materiais Moleculares (CiQUS) of the Universidade de Santiago de Compostela is the first member of a network of singular research centres with a new model of scientific organization. CiQUS is certified as a Research Centre of the Galician University System (2019-2022) and is supported by the Consellería de Educación and co-financed by the European Regional Development Fund (FEDER Galicia 2014-2020). The research developed at the centre addresses, from a multidisciplinary perspective, current challenges in the fields of health, materials science and the development of new transformative and sustainable technologies.
CiQUS/USC will employ its versatile delivery technology for non-toxic delivery of relevant cargos to immune cells, a high-value asset for industrial stakeholders working on the development of advanced therapies and nucleic acid-based therapeutics.
|
University of Debrecen
Technical Coordinator
Technical Coordinator
With its past of more than 450 years, the University of Debrecen is the oldest institution of higher education in continuous operation in Hungary. Its 14 faculties and 24 graduate schools host a student body of 30,000, making it the most versatile and one of the largest higher education institutions in Hungary. This outstanding intellectual center with vast research and development capacity has growing importance in the socioeconomic development and cultural life of the region. The institution also provides high quality patient care at all levels for the city, and advanced health services progressively up to national level, which underpins its excellence in biomedical research.
University of Debrecen will be responsible for the in vitro and in vivo comparative studies between the rewired CAR T cells and those produced by conventional protocols, including assessment of function and underlying genomic changes.
|
Leibniz Institute for Immunotherapy
The central aim of the Leibniz Institute for Immunotherapy (LIT) is research, development and application of innovative cellular therapies for the treatment of cancer, chronic inflammatory and auto-immune diseases, and organ and stem cell transplantation. Within this framework, the division of Genetic Immunotherapy headed by Prof Abken is focusing on the development of novel formats of chimeric antigen receptors (CARs) for redirecting T cells and for the modulation of cellular functions and the tissue environment through the delivery of immune modulatory products. For translation to clinical application the LIT runs a GMP facility, to manufacture cell products in close cooperation with the University Hospital Regensburg.
Building on an extensive track record in the development of CAR constructs and CAR T therapies, Leibniz Institute for Immunotherapy will execute GMP-like CAR T cell production runs using clinically applicable protocols and devices (CliniMACS Prodigy) to evaluate cell production on a clinical scale.
|
|
Follow CAR T-REX on Social Media
|
